The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 19, 2019
Filed:
Aug. 11, 2017
Applicant:
Modernatx, Inc., Cambridge, MA (US);
Inventors:
Gilles Besin, Brookline, MA (US);
Stephen Hoge, Brookline, MA (US);
Joseph Senn, Cambridge, MA (US);
Kerry Benenato, Sudbury, MA (US);
Staci Sabnis, Cambridge, MA (US);
Assignee:
ModernaTX, Inc., Cambridge, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/88 (2006.01); A61K 9/127 (2006.01); A61K 48/00 (2006.01); A61K 47/54 (2017.01); A61K 47/69 (2017.01); A61K 47/60 (2017.01); A61K 31/713 (2006.01); A61K 39/39 (2006.01); A61K 47/10 (2017.01); C08G 65/332 (2006.01); C08G 65/333 (2006.01); C08G 65/334 (2006.01); C08G 65/335 (2006.01); C12N 15/117 (2010.01); A61K 31/7115 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 48/0033 (2013.01); A61K 9/127 (2013.01); A61K 31/713 (2013.01); A61K 31/7115 (2013.01); A61K 39/39 (2013.01); A61K 47/10 (2013.01); A61K 47/543 (2017.08); A61K 47/544 (2017.08); A61K 47/60 (2017.08); A61K 47/6929 (2017.08); A61K 48/0066 (2013.01); C08G 65/3322 (2013.01); C08G 65/3326 (2013.01); C08G 65/3331 (2013.01); C08G 65/3348 (2013.01); C08G 65/3356 (2013.01); C08G 65/33306 (2013.01); C08G 65/33317 (2013.01); C08G 65/33324 (2013.01); C12N 15/117 (2013.01); C12N 15/88 (2013.01); A61K 2039/55555 (2013.01); C08G 2650/04 (2013.01); C12N 2310/141 (2013.01); C12N 2310/17 (2013.01); C12N 2320/32 (2013.01);
Abstract
This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.